Aldeyra Therapeutics: Navigating the Challenges After Reproxalap's Third CRL
Following the third Complete Response Letter for Reproxalap, Aldeyra Therapeutics is at a crossroads. This article explores the potential paths forward for the company.
Editorial Staff 3 days ago